Cesca Therapeutics Inc. (NASDAQ:KOOL) Traded 4.8% Above Its 50 Day Moving Average


The stock last traded at $3.93 marginally over $3.75, the 50 day moving average and quite a bit higher than the 200 day moving average of $3.37. The 50 day moving average was up $0.18 or +4.75% and the 200 day average moved up $0.56. (NASDAQ:KOOL) shares saw light trading volume with 637 shares changing hands by the end of trading on Tuesday. Shares saw a steep decrease in trading volume of 94.93% under the normal average daily volume.

Investors are a little more bullish on the company recently as inferred by the decrease in short interest. The company had a fall in short interest from September 15, 2017 to September 29, 2017 of -14.90%. Short interest decreased 40,151 over that timeframe. With short interest at 229,373 and short average daily volume at 18,874, the short-interest ratio is 12.0 and the short interest percentage is 0.03% as of September 29.

A few notable investment firms have updated their holdings. Kcg Holdings, Inc. cut its stake by shedding 14,045 shares a decrease of 54.2% in the quarter. Kcg Holdings, Inc. now controls 11,868 shares with a value of $39,000. The total value of its holdings decreased 56.2%. As of the end of the quarter Vanguard Group Inc had sold 61,431 shares trimming its stake by 99.9%. The value in dollars decreased from $200,000 to $0 decreasing 100.0% quarter over quarter.

As of quarter end Blackrock Inc. had disposed of a total of 146,771 shares trimming its position 99.7%. The value of the investment in KOOL went from $478,000 to $1,000 a change of $477,000 for the reporting period. As of quarter end Creative Planning had disposed of 700 shares trimming its holdings by 70.0%. The value of the investment in Cesca Therapeutics Inc. went from $3,000 to $1,000 a change of 66.7% since the last quarter.

Cesca Therapeutics Inc., launched on July 3, 1986, is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is involved in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry..